Pancreatic Cancer Research

ResearcherChangzhou No.2 People's HospitalActive in the last 2 years

Kequn Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3782-0152; OpenAlex author ID A5061691465. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
14
Papers, trials and grants by year

2018: 1 paper · 2019: 3 papers · 2020: none · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 2 papers

Papers 10

  1. LncRNA-NEAT1 inhibits the occurrence and development of pancreatic cancer through spongy miR-146b-5p/traf6. Last author DOI 10.1080/02648725.2023.2192059↗
  2. The value of a metabolic and immune-related gene signature and adjuvant therapeutic response in pancreatic cancer. Co-author DOI 10.3389/fgene.2024.1475378↗
  3. Aspirin increases the efficacy of gemcitabine in pancreatic cancer by modulating the PI3K/AKT/mTOR signaling pathway and reversing epithelial‑mesenchymal trans… Last author DOI 10.3892/ol.2023.13687↗
  4. Aspirin Regulates Gemcitabine Resistance in Pancreatic Cancer via Inhibiting the PI3K/Akt/mTOR Signaling Pathway and Reversing Epithelial-mesenchymal Transition Co-author DOI 10.21203/rs.3.rs-818856/v1↗
  5. Role of CT texture features for predicting outcome of pancreatic cancer patients with liver metastases. First author DOI 10.7150/jca.49569↗
  6. Clinical significance of site-specific metastases in pancreatic cancer: a study based on both clinical trial and real-world data. Co-author DOI 10.7150/jca.50317↗
  7. The clinical implication of CD45RA+ naïve T cells and CD45RO+ memory T cells in advanced pancreatic cancer: a proxy for tumor biology and outcome prediction. Co-author DOI 10.1002/cam4.1988↗
  8. Significance of MUC2 gene methylation detection in pancreatic cancer diagnosis. Co-author DOI 10.1016/j.pan.2019.09.012↗
  9. A Systematic Inflammation-based Model in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.30561↗
  10. Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and rea… Co-author DOI 10.1002/cam4.1573↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Feifei Wei · 4 shared papers, 2019–2024 · strength 0.70
  2. Hanyu Zhou · 5 shared papers, 2019–2023 · strength 0.68
  3. Junjie Hang · 5 shared papers, 2018–2021 · strength 0.54
  4. Lixia Wu · 5 shared papers, 2018–2021 · strength 0.54
  5. Hua Jiang · 3 shared papers, 2018–2019 · strength 0.26
  6. Siyuan Zhou · 2 shared papers, 2019–2021 · strength 0.23
  7. Danlei Ni · 1 shared paper, 2024 · strength 0.23
  8. Xuguang Yang · 2 shared papers, 2019 · strength 0.18
  9. Tiening Zhang · 1 shared paper, 2021 · strength 0.14
  10. Benny Chung-Ying Zee · 1 shared paper, 2021 · strength 0.14
  11. Yun Xiao · 1 shared paper, 2021 · strength 0.13
  12. Yuqing Cheng · 1 shared paper, 2019 · strength 0.10
  13. Junjie Huang · 1 shared paper, 2019 · strength 0.09
  14. Yuli Lin · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.